o***o
发帖数: 194 | 1 尤其对打了3针的，更严重
http://www.biorxiv.org/content/10.1101/2022.05.26.493517v1
BA.2.12.1 is only modestly (1.8-fold) more resistant to sera from vaccinated
and boosted individuals than BA.2. On the other hand, BA.4/5 is
substantially (4.2-fold) more resistant and thus more likely to lead to
vaccine breakthrough infections.
Mutation at spike residue L452 found in both BA.2.12.1 and BA.4/5
facilitates escape from some antibodies directed to the so-called Class 2
and Class 3 regions of the receptor-binding domain (RBD).
The F486V mutation found in BA.4/5 facilitates escape from certain Class 1
and Class 2 antibodies to the RBD but compromises the spike affinity for the
cellular receptor ACE2.
The R493Q reversion mutation, however, restores receptor affinity and
consequently the fitness of BA.4/5. Among therapeutic antibodies authorized
for clinical use, only bebtelovimab (LY-COV1404) retains full potency
against both BA.2.12.1 and BA.4/5.
The Omicron lineage of SARS-CoV-2 continues to evolve, successively yielding
subvariants that are not only more transmissible but also more evasive to
antibodies. | o***o
发帖数: 194 | | o***o
发帖数: 194 | 3 Cell culture experiments showed that BA.2.12.1 and BA.4/5 replicate more
efficiently in human alveolar epithelial cells than BA.2, and particularly,
BA.4/5 is more fusogenic than BA.2. Furthermore, infection experiments using
hamsters indicated that BA.4/5 is more pathogenic than BA.2. |
|
